GLI1 and skin basal cell carcinoma: 12, 13, 14, 15). Therefore, understanding the intricate molecular basis and genetic landscape of HH/GLI‐driven skin cancer,16 including microenvironmental cues and interactions with the immune system, is key to the development of improved targeted therapies, particularly for BCC patients with a priori or acquired resistance to SMOi.